Eisai Co., Ltd.: Thyroid Neoplasms trials

The registry lists 13 Thyroid Neoplasms studies with Eisai Co., Ltd. as lead sponsor. 0 are open to participants now and 6 have results posted.

Phase 1 1Phase 2 6Phase 3 2Phase 4 1No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety ProfileCompletedNCT02702388Phase 2Results posted
• A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)TerminatedNCT02657369Phase 2Results posted
• Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With OsteosarcomaCompletedNCT02432274Phase 1/2Results posted
• A Study of E7080 in Subjects With Advanced Thyroid CancerCompletedNCT01728623Phase 2Results posted
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)CompletedNCT01321554Phase 3Results posted
• Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by HistologyCompletedNCT00784303Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid CancerCompletedNCT03573960Phase 4
• Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in BrazilApproved for marketingNCT03533361
• A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in ChinaCompletedNCT02966093Phase 3
• Post-Marketing Surveillance of Lenvima in Korean PatientsCompletedNCT02764554
• Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)CompletedNCT02430714
• An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid CancerApproved for marketingNCT02211222
• Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid CancerCompletedNCT00124527Phase 2